CYP19A1 and endometrioid stromal sarcoma: Given the high expression of estrogen and progesterone receptors in LG-ESS, adjuvant endocrine therapy with aromatase inhibitors such as letrozole is often recommended (Denschlag et al., 2022, Reich et al., 2007, Wu et al., 2022).